REPLIGEN CORP Business Acquisition, Pro Forma Earnings Per Share, Diluted
REPLIGEN CORP (RGEN) reported Business Acquisition, Pro Forma Earnings Per Share, Diluted of $0.27 per share for the 12-month period ending 2014-12-31, per its 10-K filed 2016-02-25.
Discontinued › Income Statement › Earnings Per Share
us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted · last filed 2016-02-25
- REPLIGEN CORP business acquisition, pro forma earnings per share, diluted for the quarter ending 2014-09-30 was $0.04, a 80.00% decline year-over-year.
- REPLIGEN CORP business acquisition, pro forma earnings per share, diluted for the quarter ending 2014-06-30 was $0.12, a 14.29% decline year-over-year.
- REPLIGEN CORP business acquisition, pro forma earnings per share, diluted for the quarter ending 2013-09-30 was $0.20.
- REPLIGEN CORP business acquisition, pro forma earnings per share, diluted for the quarter ending 2013-06-30 was $0.14.
- REPLIGEN CORP business acquisition, pro forma earnings per share, diluted for fiscal 2014 was $0.27, a 51.79% decline from fiscal 2013.
- REPLIGEN CORP business acquisition, pro forma earnings per share, diluted for fiscal 2013 was $0.56.
| Period end | Business Acquisition, Pro Forma Earnings Per Share, Diluted 3 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 6 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 9 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.27 10-K · filed 2016-02-25 | |||
| 2014-09-30 | $0.04 10-Q · filed 2015-11-05 | $0.28 10-Q · filed 2015-11-05 | ||
| 2014-06-30 | $0.12 10-Q · filed 2014-08-11 | $0.24 10-Q · filed 2014-08-11 | ||
| 2013-12-31 | $0.56 10-K · filed 2016-02-25 | |||
| 2013-09-30 | $0.20 10-Q · filed 2014-11-07 | $0.43 10-Q · filed 2014-11-07 | ||
| 2013-06-30 | $0.14 10-Q · filed 2014-08-11 | $0.20 10-Q · filed 2014-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |